| Ytd | -87.34% | |
| 1y | -97.15% |
| Open | 4.24 | Prev Close | 4.23 | Low | 3.80 | High | 4.26 | Mkt Cap | 5.18M |
| Vol | 51.65K | Avg Vol | 692.84K | EPS | -21.90 | P/E | N/A | Forward P/E | N/A |
| Beta | 5.35 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 5.67 | 200-d Avg | 19.75 | 1yr Est | 0.00 |
Gainers Veeva Systems (NYSE:VEEV) shares increased by 8.7% to $266.15 during Wednesday's after-
Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company"), a biotechnology
FULLERTON, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminat
Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 70.3% to $9.28 during Tuesday's aft
Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company") today announced
FULLERTON, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminat
Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 48.4% to $0.16 during Thursday's regu
Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's
FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminat
Gainers Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's
Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market s
Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.6% to $0.18 during Thursday's
Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session
Gainers Exicure (NASDAQ:XCUR) stock rose 38.4% to $2.38 during Tuesday's after-market session.
Gainers VYNE Therapeutics (NASDAQ:VYNE) stock increased by 17.9% to $0.79 during Friday's pre-m
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday'
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday&#
Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's
U.S. stocks traded higher on Thursday, with the Dow gaining over 250 points. Consumer staples surged
Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 40.9% to $0.16 during Thursday's pre-
Surgepays Inc (NASDAQ: SURG) rose in pre-market trading after amending agreement with wireless netwo
Liminatus Pharma shares surged 30.49% in after-hours trading following an amended InnocsAI merger de
Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biotechnolog
FULLERTON, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminat
In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holder
FULLERTON, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminat
Major M&A deals this week include Cohere acquiring Reliant AI and Authentic Brands buys denim br
Estee Lauder (EL) shares jumped 11.8% in pre-market trading after ending discussions with Puig. Othe
FULLERTON, Calif. , May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminat
US stocks traded lower, with the Nasdaq falling 0.3%. Walmart stock dropped 7%. Oil rose 2.7% while
US stocks drop with Dow falling over 150 points. Energy shares rise, consumer staples fall. Nvidia b
The proposed merger has been approved by the boards of directors/managers of both companies and rema
Shares of elf Beauty Inc (NYSE: ELF) rose sharply in pre-market trading after beating analyst expect
Liminatus Pharma Inc. shares soared in after-hours trading after the company announced a merger agre
Liminatus Pharma Inc. shares soared in after-hours trading after the company announced a merger agre
On May 17, 2026, Liminatus Pharma, Inc. (the "Company") entered into a Merger Agreement (as
NN Inc. (NNBR) rose in pre-market trading after announcing expected sales growth and raising full-ye
Athira Pharma (NASDAQ: LONA - Get Free Report) and Liminatus Pharma (NASDAQ: LIMN - Get Free Report)
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report)
Liminatus today announced plans to initiate a Phase 1 clinical trial evaluating IBA101, a next-gener